• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    4/1/24 4:15:35 PM ET
    $GTH
    Medical Specialities
    Health Care
    Get the next $GTH alert in real time by email
    SC 13D/A 1 tm2410221d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Genetron Holdings Limited

    (Name of Issuer)

     

    Ordinary shares, par value US$0.00002 per share

    (Title of Class of Securities)

     

    37186H100**

    (CUSIP Number)

     

    Marc E. Binda

    Chief Financial Officer

    Alexandria Venture Investments, LLC

    26 North Euclid Avenue

    Pasadena, CA 91101

    (626) 578.0777

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    March 28, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    ** CUSIP number 37186H100 has been assigned to the American depositary shares (“ADSs”) of the issuer, which are quoted on The Nasdaq Global Market under the symbol “GTH.” Each ADS represents fifteen Ordinary Shares of the issuer. No CUSIP has been assigned to the Issuer’s Ordinary Shares.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   37186H100
    1. Names of Reporting Persons
    Alexandria Real Estate Equities, Inc.
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) x
      (b) ¨
    3. SEC Use Only
    4. Source of Funds (See Instructions)
    AF
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ☐
    6. Citizenship or Place of Organization
    Maryland

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
    8. Shared Voting Power
    0
    9. Sole Dispositive Power
    0
    10. Shared Dispositive Power
    0

    11. Aggregate Amount Beneficially Owned by Each Reporting Person
    0
    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ☐
    13. Percent of Class Represented by Amount in Row (11)
    0.0%
    14. Type of Reporting Person (See Instructions)
    CO

     

     

     

     

    CUSIP No.   37186H100
    1. Names of Reporting Persons
    Alexandria Venture Investments, LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) x
      (b) ¨
    3. SEC Use Only
    4. Source of Funds (See Instructions)
    WC
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ☐
    6. Citizenship or Place of Organization
    Delaware

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
    8. Shared Voting Power
    0
    9. Sole Dispositive Power
    0
    10. Shared Dispositive Power
    0
    11. Aggregate Amount Beneficially Owned by Each Reporting Person
    0
    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ☐
    13. Percent of Class Represented by Amount in Row (11)
    0.0%
    14. Type of Reporting Person (See Instructions)
    OO

     

     

     

     

    Explanatory Note: This Amendment No. 1 (the “Amendment”), which amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on October 23, 2023 (the “Original Schedule 13D”) filed on behalf of Alexandria Real Estate Equities, Inc. (“ARE”) and Alexandria Venture Investments, LLC (“AVI” and together with ARE the “Reporting Persons”), relates to the Ordinary shares, par value US$0.00002 per share (“Ordinary Shares”) of Genetron Holdings Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “Issuer”). Information reported in the Original Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Original Schedule 13D. All references in the Original Schedule 13D and this Amendment shall be deemed to refer to the Original Schedule 13D as amended and supplemented by this Amendment.

     

    Item 4.Purpose of Transaction

     

    Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end of Item 4:

     

    On March 28, 2024, Merger Sub and Parent completed the Merger with and into the Issuer, pursuant to the terms of the Merger Agreement, dated as of October 11, 2023, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, AVI contributed all of the Rollover Shares held by AVI to Parent and, in return, received equity securities of Parent. At the effective time of the Merger, each of the Rollover Shares was canceled and ceased to exist and no consideration was paid in the Merger in respect of such Rollover Shares.

     

    As a result of the Merger, the American depositary shares (each representing fifteen (15) Ordinary Shares) ceased to trade on the NASDAQ Global Market prior to the opening of trading on March 28, 2024 and became eligible for delisting from the NASDAQ Global Market, and the Ordinary Shares became eligible for termination of registration pursuant to Rules 12g-4(a)(1) and 12h-3(b)(1)(i) of the Act.

     

    Item 5.Interest in Securities of the Issuer

     

    Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a)-(b)As a result of the closing of the Merger as described in Item 4, the Reporting Persons ceased to beneficially own any Ordinary Shares or to have voting or dispositive power with respect to any Ordinary Shares. To the extent that a “group,” within the meaning of Section 13(d)(3) of the Act, was formed by virtue of the Reporting Persons’ actions with respect to the Support Agreements, such group ceased to exist upon the closing of the Merger. The information disclosed under Item 4 is hereby incorporated by reference into this Item 5.

     

    (c)Except as set forth in this Amendment, the Reporting Persons have not engaged in any transactions in the Issuer’s securities during the past 60 days prior to the obligation to file this Schedule 13D.

     

    (d)No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the Ordinary Shares beneficially owned by the Reporting Persons.

     

    (e)The Reporting Persons ceased to be, collectively with the other members of the purported “group” described in Item (5)(a)-(b), the beneficial owners of more than five percent of the Ordinary Shares on March 28, 2024.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 1, 2024

     

    ALEXANDRIA VENTURE INVESTMENTS, LLC

     

    By: Alexandria Real Estate Equities, Inc.,
    a Maryland corporation, managing member

     

    By: /s/ Marc E. Binda  
    Name: Marc E. Binda  
    Title: Chief Financial Officer and Treasurer  
         
    ALEXANDRIA REAL ESTATE EQUITIES, INC.  
         
    By: /s/ Marc E. Binda  
    Name: Marc E. Binda  
    Title: Chief Financial Officer and Treasurer  

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

     

    Get the next $GTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GTH
    SEC Filings

    View All

    SEC Form 15-12G filed by Genetron Holdings Limited

    15-12G - Genetron Holdings Ltd (0001782594) (Filer)

    4/8/24 6:04:10 AM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Genetron Holdings Limited

    S-8 POS - Genetron Holdings Ltd (0001782594) (Filer)

    3/29/24 6:02:34 AM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form 25-NSE filed by Genetron Holdings Limited

    25-NSE - Genetron Holdings Ltd (0001782594) (Subject)

    3/28/24 4:24:30 PM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genetron Health Announces Completion of Going Private Transaction

    BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the "Merger") with Genetron New Co Limited ("Merger Sub"), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and wil

    3/28/24 1:30:11 PM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health Announces Shareholders' Approval of Merger Agreement

    BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the "EGM") held today, the Company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Genetron New Co Limite

    2/21/24 6:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health to Hold Extraordinary General Meeting of Shareholders

    BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held at on February 21, 2024 at 9:00 a.m. (Beijing time) at 1/F, Building 11, Zone 1, No. 8 Life Science Parkway, Changping District, Beijing, People's Republic of China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and

    1/17/24 6:05:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Leadership Updates

    Live Leadership Updates

    View All

    Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

    BEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that the special committee (the "Special Committee") of the Company's Board of Directors (the "Board") has retained Kroll, LLC (operating through its Duff & Phelps Opinions Practice) as its independent financial advisor and Davis Polk & Wardwell LLP as its independent legal counsel. The Special Committee was formed to evaluate and consider the previously announced preliminary

    9/2/22 7:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer

    --Closes $5 million Series A financing-- --Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations-- --Announces exclusive license of TellDx platform to Genetron Holdings Limited for China-- --Secures Deployment of TellDx at ARUP Laboratories, Inc-- BEVERLY, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection and treatment of cancer through its unique and proprietary circulating tumor cell (CTC) technology, TellDx, and complementary therapeutics platform, TellRx, today announced the closing of a $5 million Series A

    5/10/21 7:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Financials

    Live finance-specific insights

    View All

    Genetron Health Reports Unaudited First Quarter 2022 Financial Results

    BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Recorded total revenue of RMB 110.3 million (US $17.4 million) in the first quarter of 2022, representing 19.8% increase over the same period in 2021. LDT revenue was RMB 81.5 million (US $12.9 million), representing 13.5% increase over the same period in 2021.IVD re

    6/2/22 7:19:58 AM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022

    BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open. Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, June 2, 2022. The conference call can be accessed by dialing the following numbers: United States:+1-833-239-5565China Domestic:400-820-528

    5/23/22 4:05:00 PM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results

    BEIJING, March 29, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2021. 2021 and Recent Business Highlights Therapy Selection: As of December 31, 2021, the Company had 58 hospital partners, of which 30 were IVD hospital partners. Genetron Health is continuing to enhance its in-hospital sales effort.

    3/29/22 7:26:05 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    4/2/24 5:44:00 PM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    4/1/24 4:15:35 PM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    3/29/24 8:04:05 AM ET
    $GTH
    Medical Specialities
    Health Care